IQVIA Holdings Inc. trades at $262.08, 6.2% below its October 23, 2026 peak of $279.36, after a third-quarter report showing revenue up 8% to $4.43 billion. The weekly uptrend is intact, but the stock sits below its 50-day average and has lagged its healthcare sector. For the next 2–6 weeks the balance of evidence is even, and conviction in that reading is low at 1 of 4 points.
Why it matters
IQV filed its quarterly report on October 27, 2026. Revenue was $4.43 billion, up 8%, net income was $350.0 million, up 6%, and diluted earnings per share were $2.10, up 9% (SEC EDGAR). That is a steady quarter with profit growing a little faster than sales. It also fits the message in a fund note that IQVIA expects revenue growth to return to mid-to-high single digits (Seeking Alpha).
Much of the good news was in the price before the numbers arrived. By October 22 the shares had risen about 79% from an April low of $154.50 and traded near $274 (CNBC). The closing peak of $279.36 came on October 23, four days before the report. The stock is up 66% over six months and 16.2% for the year, so a report that merely met a rising bar left little room for upside. Nothing in the filing or the news explains the 6.2% slide since the peak. It looks like a stock giving back part of a steep run rather than reacting to a miss.
Over five days IQV fell 3.5%. The S&P 500 (SPY) fell 2.1%, so the market explains part of it. The healthcare sector ETF (XLV) rose 2.8% over the same days, which puts IQV 6.4 points behind its sector. Most of the drop is the stock's own. The 50-day picture is similar: IQV leads the S&P 500 by 0.2 points but trails XLV by 7.8. Today's 1.4% bounce came on volume 47.6% below its 20-day average, which is thin support for a rebound.
The argument about IQV is whether a recovering business justifies a stock that has already rallied this far. The positive side is that Josh Brown sees more gains for what CNBC calls pharma's "information arms dealer", and Oakmark named IQVIA among the top contributors to its quarter (Seeking Alpha). The cautious side accepts the improvement but questions the price. One author argues that a $34.2 billion backlog does not guarantee faster earnings growth, that valuation already reflects much of the improvement, and that leverage is a risk (Seeking Alpha). Another accepts that R&D bookings are reaccelerating but says the valuation now requires execution (Seeking Alpha). Both camps agree on the business, and they differ on what it is worth.
Analysts sit firmly with the first camp. Of 18 covering the stock, the consensus is strong buy, with a mean price target of $311.89 and a range of $268 to $346. The price is 16% below the mean and under even the lowest target. That spread is wide, and targets tend to follow price rather than lead it.
What the evidence says
The long-term thesis is intact. Price is above its 40-week average, the 200-day average at $209.73 is far below the market, and IQV has beaten the S&P 500 by 21.4 points over 200 days. The stock is in a pullback phase of an uptrend after a sharp advance from the April low. It is below its 10-week average, which marks the pullback, but the longer trend has not been damaged.
For the next 2–6 weeks the balance of evidence is even, and conviction is low at 1 of 4 points. The pullback against the weekly uptrend is not yet stretched, with RSI at 50, and IQV is ahead of the market over 50 days. Against that, the stock trails its sector by 7.8 points, and the short-term and long-term signals do not point the same way, so none of the trend alignment adds to the score.
The strongest case against an even reading is a positive one. The weekly uptrend is intact, earnings grew, and analyst targets sit well above the price. That argues for the stock resuming its advance. It does not tip the balance because price is still below the 50-day average at $266.10, the bounce came on volume 47.6% below normal, and the stock has lagged a healthcare sector that is rising. That mismatch is why conviction is not higher.
Levels that matter
The structure stands above $252.15, a swing zone, and the first crack comes on a move below it. The $250 round number sits just beneath. The weekly trend ends below $245.61, another swing zone, where a decline would take out the pullback low and turn the correction into something larger. Below that, the next supports are $234.03 and $227.35.
The breakout level is a daily close above $266.10, the 50-day average, on volume above its 20-day average. From there the first target is $273.04, a swing zone, at 0.4 to 1 reward-to-risk. The second is the 52-week high of $279.36, at 0.8 to 1. The stop is $249.53, which is $252.15 minus a quarter of the 14-day average true range (ATR). The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target far beyond the 52-week high, or a much tighter stop, to get there. The $275 and $300 round numbers are the only marked resistance above the high.
What would change the picture
A weekly close below $245.61 would change the picture, because it would break the pullback low and call the long-term uptrend into question. The non-price fact that would do it is evidence that pharma R&D bookings are slowing. The bullish argument rests on the reaccelerating bookings (19% growth in the second quarter) turning into faster revenue, and a fade there would undercut the case for a price near the highs.
What to watch
- Earnings: the third-quarter report came on October 27, 2026, and no later date is listed. The number that matters in the next one is revenue growth against this quarter's 8%, and whether it holds in the mid-to-high single digits.
- Sector: XLV is up 10.9% over a month, and its customers are reporting strong quarters, such as Supernus with record revenue of $226.8 million. More results from drug developers would show whether their spending on trials and data is holding up.
- Valuation: at $262.08, the stock is 16% below the $311.89 mean target and below the lowest target of $268.